BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Varghese L, Curran D, Bunge E, Vroling H, van Kessel F, Guignard A, Casabona G, Olivieri A. Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK. Public Health 2017;142:46-9. [PMID: 28057197 DOI: 10.1016/j.puhe.2016.10.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ramírez M, Santos S, Martínez O, Rodríguez R, Miranda E, Ramos-Perez WD, Otero M. Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA. Vaccine 2018;36:2049-55. [PMID: 29525282 DOI: 10.1016/j.vaccine.2018.02.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Buchan SA, Daneman N, Wang J, Garber G, Wormsbecker AE, Wilson SE, Deeks SL. Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002-2016. Clin Infect Dis 2020;71:22-9. [PMID: 31436814 DOI: 10.1093/cid/ciz769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Jia S, Li J, Liu Y, Zhu F. Precision immunization: a new trend in human vaccination. Hum Vaccin Immunother 2020;16:513-22. [PMID: 31545124 DOI: 10.1080/21645515.2019.1670123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Orrico-Sánchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014. BMC Infect Dis 2020;20:905. [PMID: 33256624 DOI: 10.1186/s12879-020-05648-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, Espie E, Bianco V. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open 2018;8:e020528. [PMID: 29880565 DOI: 10.1136/bmjopen-2017-020528] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
6 Bloom DC, Tran RK, Feller J, Voellmy R. Immunization by Replication-Competent Controlled Herpesvirus Vectors. J Virol 2018;92:e00616-18. [PMID: 29899091 DOI: 10.1128/JVI.00616-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kling K, Wichmann O, Burchard G. [Travel vaccinations for certain groups of persons]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:85-92. [PMID: 31811312 DOI: 10.1007/s00103-019-03067-w] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Lutz J, Rieke A, Rieke B. [Traveling with immunodeficiency-Problems and prevention]. Internist (Berl) 2019;60:701-8. [PMID: 31098645 DOI: 10.1007/s00108-019-0617-4] [Reference Citation Analysis]
9 Rosenberg Danziger C, Anis E, Gordon ES, Grotto I, Danon YL. Reintroducing OPV in Israel on the journey to global polio eradication - Estimation at a low rate of contraindicated population. Vaccine 2018;36:3717-20. [PMID: 29776752 DOI: 10.1016/j.vaccine.2018.05.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]